drugset / Trial / NCT05735496
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Phase 1
Active not recruiting
219 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB102 injection in subjects with advanced malignancies.
Timeline
- Start
- 2023-03-09
- Primary completion
- 2025-07-21
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2102 | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | TQB2102 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | TQB2102 | Monoclonal antibody | 4.5 mg/kg | Intravenous |
| Subject | TQB2102 | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | TQB2102 | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | TQB2102 | Monoclonal antibody | 9 mg/kg | Intravenous |